Skip to content

FDA Clears First Automated Free Testosterone Test: 99% Accuracy Achieved

Revvity has received FDA clearance for the first automated free testosterone test, which boasts an impressive 99% accuracy rate. This test, known as the “Revvity Safe Biopharma,” is designed to measure free testosterone levels in human serum or plasma. The test’s automation reduces the need for manual labor, potentially decreasing errors and increasing efficiency in labs. Revvity’s third-quarter earnings for 2024 show a significant increase in recurring revenues, with diagnostics playing a key role. The company’s earnings call highlighted the importance of this new test in their portfolio, projecting a positive impact on future earnings. The test’s introduction marks a milestone in diagnostic technology, offering a reliable, automated solution for assessing free testosterone levels, which is crucial for diagnosing various health conditions.

Source: seekingalpha.com

Related Videos